Comment from Amgen

Summary: Amgen, a global biotechnology and pharmaceutical company, supports the FDA's pilot program to explore AI-enabled optimization of early-phase clinical trials. They advocate for focusing on high-impact, implementation-ready use cases, establishing clear learning objectives, and ensuring AI trustworthiness through robust governance and transparent knowledge sharing.